PYC Therapeutics Limited Share Price
Stocks
PYC
AU000000PYC7
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.130 AUD | +1.43% |
|
+27.16% | +28.70% |
| 04/08 | ASX Biggest Gainers | MT |
| 29/07 | PYC Therapeutics Secures Approval for Higher Dosage in Phase 1b Multiple Ascending Dose Study in Polycystic Kidney Disease | MT |
| Market Cap | 206.54Cr 145.71Cr 126.2Cr 117.64Cr 108.19Cr 204.26Cr 14TCr 1.38TCr 542.56Cr 6.93TCr 547.24Cr 535.18Cr 23TCr | P/E 2026 * |
-29.9x | P/E 2027 * | -22.8x |
|---|---|---|---|---|---|
| Enterprise Value | 140.11Cr 99Cr 86Cr 80Cr 73Cr 138.56Cr 9.4TCr 937.77Cr 368.06Cr 4.7TCr 371.24Cr 363.05Cr 16TCr | EV / Sales 2026 * |
382x | EV / Sales 2027 * | - |
| Free-Float |
70.64% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: PYC Therapeutics Limited
| 17/03 | Bell Potter rates PYC as Speculative Buy | AQ |
| 09/25/09 | Bell Potter rates PYC as Speculative Buy | AQ |
| 07/24/07 | PYC Therapeutics : Anti Bribery & Anti Corruption Policy | PU |
| 07/24/07 | PYC Therapeutics : Definition of Independence | PU |
| 07/24/07 | PYC Therapeutics : Continuous Disclosure Policy | PU |
| 1 day | +1.43% | ||
| 1 week | +27.16% | ||
| Current month | +25.29% | ||
| 1 month | +36.98% | ||
| 3 months | +82.83% | ||
| 6 months | +42.00% | ||
| Current year | +28.70% |
| 1 week | 1.68 |  | 2.18 |
| 1 month | 1.49 | | 2.18 |
| Current year | 1.04 | | 2.18 |
| 1 year | 0.85 | | 2.18 |
| 3 years | 0.52 | | 2.18 |
| 5 years | 0.5 | | 2.18 |
| 10 years | 0.14 | | 2.18 |
| Manager | Title | Age | Since |
|---|---|---|---|
Rohan Hockings
CEO | Chief Executive Officer | 42 | 19/08/2020 |
Thomas Ulmer
DFI | Director of Finance/CFO | 47 | 07/07/2026 |
Sri Mudumba
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Rohan Hockings
BRD | Director/Board Member | 42 | 30/11/2018 |
Ian Constable
BRD | Director/Board Member | - | 22/09/2025 |
Peter Coleman
CHM | Chairman | 66 | 18/11/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 23/12/25 | Free | Chairman | 20,00,000 | 0.3429% | ||
| 26/11/25 | Buy | Chief Executive Officer | 1,33,350 | 0.0229% | ||
| 27/02/25 | Australia Land Pty Ltd.
| Buy | Company | 2,80,00,000 | 6.0008% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.43% | +27.16% | +63.85% | +267.24% | 145.71Cr | |
| +1.07% | -0.70% | +3.81% | +15.50% | 4.86TCr | |
| +1.98% | +9.05% | +413.94% | +532.17% | 4.19TCr | |
| +3.44% | -4.65% | +28.34% | +8.81% | 3.89TCr | |
| +1.40% | +0.10% | +6.61% | +61.93% | 3.72TCr | |
| +2.42% | +5.72% | +12.38% | +44.79% | 3.07TCr | |
| -0.16% | -3.11% | - | - | 1.61TCr | |
| +2.20% | +0.48% | +34.71% | +127.15% | 1.64TCr | |
| +0.40% | +2.04% | +8.36% | +19.21% | 1.4TCr | |
| +4.25% | -8.23% | -1.49% | -35.46% | 1.26TCr | |
| Average | +1.85% | +2.22% | +63.39% | +115.70% | 2.58TCr | |
| Weighted average by Cap. | +1.91% | +0.05% | +82.89% | +121.60% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 36.67L 25.87L 22.4L 20.88L 19.21L 36.26L 25Cr 2.45Cr 96.32L 12Cr 97.15L 95.01L 41Cr | - |
| Net income | -5.74Cr -4.05Cr -3.51Cr -3.27Cr -3.01Cr -5.68Cr -385.26Cr -38Cr -15Cr -192.76Cr -15Cr -15Cr -638.42Cr | -8.58Cr -6.05Cr -5.24Cr -4.88Cr -4.49Cr -8.48Cr -575.22Cr -57Cr -23Cr -287.81Cr -23Cr -22Cr -953.2Cr |
| Net Debt | -66Cr -47Cr -41Cr -38Cr -35Cr -66Cr -4.46TCr -444.6Cr -174.5Cr -2.23TCr -176Cr -172.12Cr -7.38TCr | -58Cr -41Cr -35Cr -33Cr -30Cr -57Cr -3.88TCr -387.37Cr -152.04Cr -1.94TCr -153.35Cr -149.97Cr -6.43TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/26/06 | A$2.130 | +1.43% | 33,60,149 |
| 05/26/05 | A$2.100 | +5.26% | 33,23,845 |
| 04/26/04 | A$1.995 | +9.62% | 34,35,046 |
| 03/26/03 | A$1.820 | +7.06% | 23,71,962 |
| 31/26/31 | A$1.700 | +1.49% | 6,65,496 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- PYC Stock
Select your edition
All financial news and data tailored to specific country editions
